New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
06:20 EDTINFI, ARIA, GILDGilead seeks more blood cancer drug deals, Bloomberg reports
Gilead Sciences (GILD) has spent $1.2B in two years to buy blood cancer drugs, and wants more, reports Bloomberg. Treatment for leukemia and other blood cancers is one of the fastest growing markets for cancer drugs. Gilead COO John Milligan said the company is eyeing possible new deals. They could include Ariad Pharmaceuticals (ARIA) and Infinity Pharmaceuticals (INFI), said Raghuram Selvaraju, at Aegis Capital Corp. Reference Link
News For GILD;ARIA;INFI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 26, 2015
05:34 EDTGILDGilead Sovaldi approved in Japan
Gilead Sciences announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, has approved Sovaldi, a once-daily nucleotide analog polymerase inhibitor, for the suppression of viremia in patients with genotype 2 chronic hepatitis C virus, or HCV, infection with or without compensated cirrhosis. Sovaldi is indicated for use in combination with ribavirin, or RBV, for 12 weeks. Sovaldi is the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection. Sovaldi is also the first product to be marketed by Gilead in Japan.
March 25, 2015
16:00 EDTGILDOptions Update; March 25, 2015
Subscribe for More Information
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA KRFT FB BIDU GPRO V GILD NFLX
09:29 EDTARIAARIAD reports dismissal of class action suit in federal district court
ARIAD Pharmaceuticals announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy. The suit alleged that certain of the company defendants made a series of false and misleading statements regarding the safety, efficacy and commercial prospects of Iclusig. The Court granted the company’s motion to dismiss the lawsuit, concluding that the plaintiffs failed to establish that any such statements violated the company’s disclosure obligations as asserted in the complaint. “We are pleased that for the second time in as many weeks, the Court has granted our motion to dismiss what we believed from the outset was another meritless lawsuit,” said Harvey J. Berger, M.D., chairman and CEO. “Our corporate values of integrity and mutual respect are always at the forefront as we continue to focus on executing our plan for sustained revenue growth and operational excellence, leading to anticipated profitability in 2018.”
March 24, 2015
09:22 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
08:00 EDTGILDGilead shares should be bought on weakness, says Bernstein
Subscribe for More Information
07:37 EDTARIAARIAD announces approval of Iclusig in Israel
ARIAD Pharmaceuticals and Medison Pharma announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig, ponatinib, in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in Q2.
March 23, 2015
16:01 EDTGILDOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
11:45 EDTGILDGilead defended after slide following death of Hep C patient on heart drug
Subscribe for More Information
11:32 EDTGILDStocks with call strike movement; GILD CELG
Gilead (GILD) August 115 call option implied volatility increased 5% to 27, Celgene (CELG) July 140 call option implied volatility increased 3% to 28 according to IVolatility.
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
08:44 EDTGILDGilead volatility low into FDA hepatitis C drug warning
Subscribe for More Information
08:23 EDTGILDGilead weakness a buying opportunity, says RW Baird
Subscribe for More Information
07:40 EDTGILDGilead weakness on FDA warning would be buying opportunity, says Wells Fargo
Subscribe for More Information
06:08 EDTGILDGilead implied volatility of 23 at lower end of index mean range
Subscribe for More Information
March 22, 2015
15:05 EDTGILDGilead warns after hepatitis C patient taking heart drug dies, Bloomberg says
Gilead said in an e-mailed drug warning to health-care providers on Friday that nine patients taking its hepatitis C drugs Harvoni or Sovaldi along with the heart treatment amiodarone developed abnormally slow heartbeats and one died of cardiac arrest, says Bloomberg. Reference Link
March 20, 2015
16:00 EDTGILDOptions Update; March 20, 2015
Subscribe for More Information
15:02 EDTGILDAcelRx names Howard Rosen as interim CEO
AcelRx Pharmaceuticals (ACRX) announced the appointment of Howard Rosen as interim CEO of AcelRx, effective April 1. Rosen is a technically trained executive with over 25 years of success growing start-up and mid-size biopharmaceutical companies. Rosen previously held senior-level general management positions and functional roles in strategy, marketing, finance, business development, and research and development at Gilead Sciences (GILD) and ALZA Corporation. Rosen has served on the Board of Directors of AcelRx since 2008 and currently serves on the Board of Directors of Alcobra and several private biopharmaceutical companies.
March 19, 2015
16:01 EDTGILDOptions Update; March 19, 2015
Subscribe for More Information
09:08 EDTGILDNew Gilead HIV drug likely to be approved in mid-2015, says Argus
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use